hi all

as one who has been on selegiline since 1988
i question the terminology "amphetamine-like effect".
it has been described more precisely in other literature.
while selegiline has symptomatic benefits in pd,
it certainly doesn't produce a 'high' as in 'speed'!
hmm, i wonder who wiley-liss is/are?

janet

---------------------------------------------------------
Neuroprotective actions of selegiline.

Selegiline, a selective inhibitor of monoamine oxidase-B (MAO-B), was one
of the first adjunct therapies in clinical neurology.

A retrospective analysis of data from patients with Parkinson's disease
found a significant increase in survival in those treated with selegiline
plus L-dopa compared with L-dopa alone.

The mechanism of action of selegiline is complex and cannot be explained
solely by its MAO-B inhibitory action.

Pretreatment with selegiline can protect neurons against a variety of
neurotoxins, such as 1-methyl- 4-phenyl -1,2,3,6 tetrahydropyridine (MPTP),
6-hydroxydopamine, N-(2-chloroethyl) -N-ethyl- 2-bromobenzylamine (DSP-4),
methyl- beta- acetoxyethyl- 2-chloroethylamine (AF64A), and
5,6-dihydroxyserotonin, which damage dopaminergic, adrenergic, cholinergic,
and sertoninergic neurons, respectively.

Selegiline produces an amphetamine-like effect, enhances the release of
dopamine, and blocks the reuptake of dopamine.

It stimulates gene expression of L-aromatic amino acid decarboxylase,
increases striatal phenylethylamine levels, and activates dopamine
receptors. Selegiline reduces the production of oxidative radicals,
up-regulates superoxide dismutase and catalase, and suppresses nonenzymatic
and iron-catalyzed autooxidation of dopamine.

Selegiline compensates for loss of target-derived trophic support, delays
apoptosis in  serum-deprived cells, and blocks apoptosis-related fall in
the mitochondrial membrane potential.

Most of the aforementioned properties occur independently of selegiline's
efficacy to inhibit MAO-B.

Copyright 2002 Wiley-Liss, Inc.

J Neurosci Res 2002 Feb 1;67(3):285-289 [epub ahead of print]
Ebadi M, Sharma S, Shavali S, El Refaey H.
University of North Dakota School of Medicine and Health Sciences, North
Dakota, USA
PMID: 11967969
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list
_uids=11967969&dopt=Abstract

janet paterson: an akinetic rigid subtype, albeit perky, parky
pd: 55/41/37 cd: 55/44/43 tel: 613 256 8340 email: [log in to unmask]
smail: 375 Country Street, Almonte, Ontario, Canada, K0A 1A0
a new voice: http://www.geocities.com/janet313/

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn